Definitional
Sermorelin is the synthetic 29-amino-acid GHRH (1-29) fragment, and several of the most common questions are simply asking what it is and how it works.
What is Sermorelin?
Sermorelin is a synthetic 29-amino-acid peptide corresponding to the bioactive N-terminal fragment of growth hormone-releasing hormone (GHRH 1-29), studied as a stimulator of endogenous growth hormone secretion 0107. The molecule has a molecular weight of 3,357.9 Da and the sequence Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2.
What does Sermorelin do to the body?
Binds the GHRH receptor on anterior pituitary somatotrophs, stimulating pulsatile release of endogenous human growth hormone, which in turn drives hepatic IGF-1 production 0107. The effect operates within the body's preserved negative-feedback architecture from somatostatin and circulating IGF-1.
How does Sermorelin work?
Engages pituitary GHRH receptors to amplify the body's natural GH pulse rather than supplying exogenous GH; the effect is downstream-physiologic, not replacement 07. Continuous (non-pulsatile) administration produces tachyphylaxis at the somatotroph, which is why published trials use intermittent bedtime dosing 18.
What is Sermorelin used for in research?
Historically studied as a diagnostic for pituitary GH reserve (1 mcg/kg IV provocative test) and as a treatment for pediatric idiopathic GH deficiency (30 mcg/kg SC at bedtime) 0306; later research explores adult-onset GH decline 091021. Modern reviews place Sermorelin primarily in the GH-secretagogue pharmacology class 12.
Safety and Efficacy
Is Sermorelin safe?
Generally well tolerated in clinical trials; the most common adverse events were transient injection-site reactions in the pediatric international multi-site study group cohort and across the adult research literature 0309. Serum cortisol, prolactin, and thyroid-axis disturbances are not characteristic. Long-term safety data in adults remains limited because long-duration adult trials are sparse.
Does Sermorelin work?
Clinical trials report measurable increases in serum GH and IGF-1 versus baseline; magnitude and clinical relevance vary by population studied 030910. The strongest efficacy data is in pediatric idiopathic GHD, where height-velocity acceleration was clinically meaningful at 30 mcg/kg subcutaneously nightly 03.
What are the downsides of Sermorelin?
Short plasma half-life of approximately 11-12 minutes requires frequent dosing 05; effect is blunted or absent in patients with intrinsic pituitary failure because there are no somatotrophs to stimulate 08; tachyphylaxis is observed with continuous (non-pulsatile) administration, requiring intermittent bedtime dosing 18.
Who should not use Sermorelin?
Active malignancy, intracranial lesions, and known hypersensitivity are exclusion criteria in published trials. The proliferative-axis concern with active malignancy applies broadly to GH and IGF-1 secretagogues 20. Pediatric trials enrolled prepubertal children with idiopathic GHD as the principal population 03.
What not to mix with Sermorelin?
Glucocorticoids and certain antithyroid agents have been reported to blunt the GH response to GHRH analogs in clinical pharmacology studies 18. Concomitant somatostatin analogs are mechanistically antagonistic; concurrent recombinant GH is mechanistically redundant.
Are there long-term side effects of Sermorelin?
Long-duration trials are sparse; theoretical concerns include insulin resistance and IGF-1-mediated effects, though clinical signals in the available Sermorelin literature have been modest 09. The broader GH-axis literature documents these concerns more thoroughly because the recombinant-GH and tesamorelin trial durations have been longer 1320.
How long can you stay on Sermorelin?
Published trial durations have ranged from single-dose pharmacodynamic studies to approximately 12 months of nightly dosing in pediatric GHD 0304. Adult research durations have typically been shorter — Khorram's 16-week cohort is representative of the longer adult published exposures 09.
Pharmacokinetics, Dosing, Administration
What is Sermorelin half-life?
Plasma half-life is short, on the order of 10-20 minutes — Frohman and colleagues reported approximately 11-12 minutes after IV or SC dosing in adults 05. The GH-secretory pharmacodynamic effect persists 2-4 hours despite the short plasma half-life 12.
How is Sermorelin dosed in clinical studies?
Pediatric idiopathic GHD trials used 30 mcg/kg subcutaneously at bedtime 03. The pediatric diagnostic provocative test used 1 mcg/kg IV 06. Adult research has used 10 mcg/kg subcutaneously nightly 09 or fixed-microgram regimens in the 0.2-0.5 mg range nightly. Framing throughout is studied-at, not prescriptive.
Where is Sermorelin injected in studies?
Subcutaneous injection, typically into the abdomen or thigh, administered at bedtime to align with the body's nocturnal GH pulse 0309. The intravenous route is reserved for diagnostic provocative testing at 1 mcg/kg 06.
Storage and Stability
Lyophilized Sermorelin is stable refrigerated; once reconstituted, stability declines and refrigeration is standard per published handling guidance. The molecule is susceptible to N-terminal proteolytic degradation in plasma — the basis for the short plasma half-life 05.
Classification and Class Comparisons
Is Sermorelin a Steroid?
No. Sermorelin is a peptide (a short chain of amino acids), not a steroid. It acts on the GHRH receptor, a class B G-protein-coupled receptor 0107, not on nuclear steroid receptors. The mechanism of action and the regulatory category are unrelated to anabolic-androgenic steroids.
Is Sermorelin HGH?
No. Sermorelin is a GHRH analog that stimulates the pituitary to release endogenous human growth hormone; it is not itself growth hormone. The upstream mechanism is the structural distinction from recombinant hGH replacement therapy, which supplies exogenous GH directly 20.
Is Sermorelin a GLP-1?
No. Sermorelin is a GHRH analog acting on the pituitary GHRH receptor; GLP-1 agonists act on incretin pathways in the pancreas and elsewhere. The mechanisms, receptor families, and therapeutic categories are unrelated.
How does Sermorelin compare to Ipamorelin?
Sermorelin is a GHRH-receptor agonist; Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist 14. The two stimulate GH release through distinct receptors on the same somatotroph population and are sometimes studied together for supra-additive effect 1215.
How does Sermorelin compare to Tesamorelin?
Both are GHRH analogs. Tesamorelin is a longer GHRH 1-44 analog stabilized with a trans-3-hexenoic acid modification, with substantially longer half-life and an FDA indication for HIV-associated lipodystrophy 13.
Can Tesamorelin and Sermorelin be combined?
Both act on the same GHRH receptor, so combining them is mechanistically redundant rather than additive; the published literature does not support combined dosing within the GHRH-analog class. Combination across classes — GHRH analog with a GHRP — is the supra-additive pharmacology 1215.
Regulatory and Demographic
Is Sermorelin FDA-approved?
Sermorelin acetate (under the historical FDA-approved branded product) was FDA-approved in 1997 for pediatric idiopathic GH deficiency at 30 mcg/kg/day subcutaneously, and was voluntarily discontinued from the US market in 2008 for commercial — not safety — reasons 17. No FDA-approved branded Sermorelin product is currently marketed; compounded preparations exist under the FDA 503A/503B framework.
Regulatory Status
Sermorelin is a prescription substance in the US (no current FDA-approved branded product since 2008; compounded preparations exist) 17. WADA prohibits Sermorelin and other GHRH analogs for competitive athletes under the S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics category.
What does Sermorelin do for men in research contexts?
Research in adult men has examined Sermorelin's effects on the somatotropic axis and IGF-1, with attention to age-related GH decline 0910. The Khorram 16-week cohort reported elevated nocturnal GH, elevated IGF-1, and lean body mass gain in the male subgroup 09; Vittone reported restored youthful 24-h GH patterns in elderly men 10.
Can women use Sermorelin in research settings?
Yes — pediatric GHD research enrolled both sexes 0304, and adult studies have included female participants, though sex-disaggregated outcome data are sparser. Khorram's 16-week cohort enrolled nineteen men and women aged 55-71, with skin thickness increasing in both sexes 09.
Combining GHRH Analogs
Both Sermorelin and tesamorelin act on the same GHRH receptor, so combining GHRH analogs is mechanistically redundant rather than additive. The supra-additive combination pharmacology is GHRH + GHRP (across receptor classes), not GHRH + GHRH (within receptor class) 1215.